566 results on '"Regierer, A."'
Search Results
52. OP0045 EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER
- Author
-
Sebbag, E., primary, Lauper, K., additional, Molina Collada, J., additional, Aletaha, D., additional, Askling, J., additional, Benesova, K., additional, Bertheussen, H., additional, Bitoun, S., additional, Bolek, E. C., additional, Burmester, G. R., additional, Canhão, H., additional, Chatzidionysiou, K., additional, Curtis, J., additional, Danlos, F. X., additional, Guimaraes, V., additional, Hetland, M. L., additional, Iannone, F., additional, Kostine, M., additional, Kragstrup, T. W., additional, Kvien, T. K., additional, Regierer, A., additional, Schulze-Koops, H., additional, Silva-Fernández, L., additional, Szekanecz, Z., additional, Buch, M. H., additional, Finckh, A., additional, and Gottenberg, J. E., additional
- Published
- 2023
- Full Text
- View/download PDF
53. The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study
- Author
-
Anne C. Regierer, Anja Weiß, Uta Kiltz, Joachim Sieper, Ilka Schwarze, Martin Bohl-Bühler, Herbert Kellner, Denis Poddubnyy, Angela Zink, Jürgen Braun, Joachim Listing, and Anja Strangfeld
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy - Abstract
ObjectiveThe Assessment of Spondyloarthritis international Society Health Index (ASAS HI) measures global functioning and health in patients with axial spondyloarthritis (axSpA) covering domains of physical, emotional, and social functioning. The main aim of this study was to investigate the sensitivity to change of ASAS HI in comparison with established variables of disease activity, function, and mental health.MethodsPatients with axSpA from the disease register RABBIT-SpA with follow-up time of at least 12 months and available ASAS HI questionnaires were included. Patients received questionnaires addressing disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], Ankylosing Spondylitis Disease Activity Score [ASDAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]), mental health (5-item World Health Organization Well-Being Index [WHO-5]), and global functioning (ASAS HI). Standardized response means (SRMs) were calculated to compare the sensitivity to change of different variables.ResultsSix hundred and sixty-seven patients were included, 552 treated with biologic disease-modifying antirheumatic drugs (bDMARDs) and 115 with conventional synthetic DMARDs and/or nonsteroidal antiinflammatory drugs (control group). Between baseline and month 12, the mean ASAS HI declined from 6.9 to 5.1 in the bDMARD group and from 5.9 to 5.6 in the conventionally treated group. In the bDMARD group, the SRM of ASAS HI was 0.52, compared to 0.59 for BASFI, 0.65 for WHO-5, 0.73 for BASDAI, and 0.90 for ASDAS. The following ASAS HI domains were most frequently affected: pain (78% agreed), maintaining body position (75%), and energy/drive (73%). In the patients receiving bDMARDs, there was an improvement in all items. In the control group, the largest improvement was seen in pain.ConclusionAs expected, ASDAS and BASDAI as disease activity scores showed high sensitivity to change, whereas changes in physical function (BASFI), mental health (WHO-5), and the broader concept of functioning and health (ASAS HI) were moderate.
- Published
- 2022
54. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis
- Author
-
Machado, Pedro M, Schäfer, Martin, Mahil, Satveer K, Liew, Jean, Gossec, Laure, Dand, Nick, Pfeil, Alexander, Strangfeld, Anja, Regierer, Anne Constanze, Fautrel, Bruno, Alonso, Carla Gimena, Saad, Carla G S, Griffiths, Christopher E M, Lomater, Claudia, Miceli-Richard, Corinne, Wendling, Daniel, Alpizar Rodriguez, Deshire, Wiek, Dieter, Mateus, Elsa F, Sirotich, Emily, Soriano, Enrique R, Ribeiro, Francinne Machado, Omura, Felipe, Rajão Martins, Frederico, Santos, Helena, Dau, Jonathan, Barker, Jonathan N, Hausmann, Jonathan, Hyrich, Kimme L, Gensler, Lianne, Silva, Ligia, Jacobsohn, Lindsay, Carmona, Loreto, Pinheiro, Marcelo M, Zelaya, Marcos David, Severina, María de Los Ángeles, Yates, Mark, Dubreuil, Maureen, Gore-Massy, Monique, Romeo, Nicoletta, Haroon, Nigil, Sufka, Paul, Grainger, Rebecca, Hasseli, Rebecca, Lawson-Tovey, Saskia, Bhana, Suleman, Pham, Thao, Olofsson, Tor, Bautista-Molano, Wilson, Wallace, Zachary S, Yiu, Zenas Z N, Yazdany, Jinoos, Robinson, Philip C, Smith, Catherine H, Centro de Estudos de Doenças Crónicas (CEDOC), and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
- Subjects
SDG 3 - Good Health and Well-being - Abstract
Funding The study received support from the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR). OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. RESULTS: Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. CONCLUSION: Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics. publishersversion published
- Published
- 2023
55. Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
- Author
-
Hasseli, Rebecca, primary, Richter, Jutta G., additional, Hoyer, Bimba Franziska, additional, Lorenz, Hanns-Martin, additional, Pfeil, Alexander, additional, Regierer, Anne Constanze, additional, Schmeiser, Tim, additional, Strangfeld, Anja, additional, Voll, Reinhard E, additional, Krause, Andreas, additional, Reckert, Sabine, additional, Gräßler, Anett, additional, Saar, Petra, additional, Kapelle, Andreas, additional, Backhaus, Marina, additional, Blank, Norbert, additional, Henes, Joerg, additional, Osiek, Silke, additional, Knothe, Anna, additional, Hoese, Guido, additional, Brandt-Jürgens, Jan, additional, Maltzahn, Anja, additional, Specker, Christof, additional, Müller-Ladner, Ulf, additional, and Schulze-Koops, Hendrik, additional
- Published
- 2023
- Full Text
- View/download PDF
56. High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex
- Author
-
Albrecht, Katinka, primary, Regierer, Anne Constanze, additional, Strangfeld, Anja, additional, Marschall, Ursula, additional, and Callhoff, Johanna, additional
- Published
- 2023
- Full Text
- View/download PDF
57. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
- Author
-
Regierer, Anne Constanze, primary, Weiß, Anja, additional, Proft, Fabian, additional, Baraliakos, Xenofon, additional, Behrens, Frank, additional, Poddubnyy, Denis, additional, Schett, Georg, additional, Lorenz, Hanns-Martin, additional, Worsch, Matthias, additional, and Strangfeld, Anja, additional
- Published
- 2023
- Full Text
- View/download PDF
58. Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany
- Author
-
Albrecht, Katinka, primary, Binder, Sebastian, additional, Minden, Kirsten, additional, Poddubnyy, Denis, additional, Regierer, Anne C., additional, Strangfeld, Anja, additional, and Callhoff, Johanna, additional
- Published
- 2023
- Full Text
- View/download PDF
59. Die Hälfte der Personen mit Psoriasis-Arthritis ist von Polypharmazie betroffen
- Author
-
Callhoff, J, Albrecht, K, Regierer, A, Strangfeld, A, Marschall, U, Callhoff, J, Albrecht, K, Regierer, A, Strangfeld, A, and Marschall, U
- Published
- 2023
60. Inzidente Malignomerkrankungen in RA-Patient:innen der rheumatologischen Routineversorgung
- Author
-
Schäfer, M, Meissner, Y, Manger, B, Berger, S, Rockwitz, K, Regierer, A, Strangfeld, A, Schäfer, M, Meissner, Y, Manger, B, Berger, S, Rockwitz, K, Regierer, A, and Strangfeld, A
- Published
- 2023
61. Vergleich von klinischen Parametern von PsA-Patient:innen bei Einleitung einer bDMARD/tsDMARD-Therapie entweder als Monotherapie oder als MTX-Kombinationstherapie - eine Analyse von RABBIT-SpA-Daten
- Author
-
Regierer, A, Kiefer, D, Schett, G, Krause, A, Sewerin, P, Weiß, A, Strangfeld, A, Regierer, A, Kiefer, D, Schett, G, Krause, A, Sewerin, P, Weiß, A, and Strangfeld, A
- Published
- 2023
62. Vergleich von TNFi und Secukinumab in der Erst- und Zweitlinientherapie der axSpA - eine Analyse von RABBIT-SpA-Daten
- Author
-
Regierer, A, Baraliakos, X, Poddubnyy, D, Marycz, T, Weiß, A, Strangfeld, A, Regierer, A, Baraliakos, X, Poddubnyy, D, Marycz, T, Weiß, A, and Strangfeld, A
- Published
- 2023
63. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
- Author
-
Anne Constanze Regierer, Anja Weiß, Fabian Proft, Xenofon Baraliakos, Frank Behrens, Denis Poddubnyy, Georg Schett, Hanns-Martin Lorenz, Matthias Worsch, and Anja Strangfeld
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,ddc:610 - Abstract
BackgroundPsoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) show certain overlaps: A subset of patients with PsA can develop axial involvement (axial PsA, axPsA), while a subset of patients with axSpA presents with psoriasis (axSpA+pso). Treatment strategy for axPsA is mostly based on axSpA evidence.ObjectivesTo compare demographic and disease-specific parameters of axPsA and axSpA+pso.MethodsRABBIT-SpA is a prospective longitudinal cohort study. AxPsA was defined based on (1) clinical judgement by rheumatologists; (2) imaging (sacroiliitis according to modified New York criteria in radiographs or signs of active inflammation in MRI or syndesmophytes/ankylosis in radiographs or signs of active inflammation in spine MRI). axSpA was stratified into axSpA+pso and axSpA without pso.ResultsPsoriasis was documented in 181/1428 axSpA patients (13%). Of 1395 PsA patients, 359 (26%) showed axial involvement. 297 patients (21%) fulfilled the clinical definition and 196 (14%) the imaging definition of axial manifestation of PsA. AxSpA+pso differed from axPsA regardless whether clinical or imaging definition was used. axPsA patients were older, more often female and less often HLA-B27+. Peripheral manifestations were more often present in axPsA than in axSpA+pso, whereas uveitis and inflammatory bowel disease were more common in axSpA+pso. Burden of disease (patient global, pain, physician global) was similar among axPsA and axSpA+pso patients.ConclusionsAxPsA differs from axSpA+pso in its clinical manifestations, irrespective of whether axPsA is defined clinically or by imaging. These findings support the hypothesis that axSpA and PsA with axial involvement are distinct entities, so extrapolation of treatment data from randomised controlled trials in axSpA should be performed with caution.
- Published
- 2023
64. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis:data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
- Author
-
Pedro M Machado, Martin Schäfer, Satveer K Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G S Saad, Christopher E M Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F Mateus, Emily Sirotich, Enrique R Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajão Martins, Helena Santos, Jonathan Dau, Jonathan N Barker, Jonathan Hausmann, Kimme L Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M Pinheiro, Marcos David Zelaya, María de los Ángeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S Wallace, Zenas Z N Yiu, Jinoos Yazdany, Philip C Robinson, and Catherine H Smith
- Subjects
Adult ,Male ,Ankylosing ,Aging ,Clinical Sciences ,Immunology ,Psoriatic ,Autoimmunity ,Autoimmune Disease ,General Biochemistry, Genetics and Molecular Biology ,Rheumatology ,Clinical Research ,Physicians ,Humans ,Psoriasis ,Immunology and Allergy ,Registries ,Glucocorticoids ,Arthritis ,COVID-19 ,Interleukin-12 ,Arthritis & Rheumatology ,Good Health and Well Being ,Public Health and Health Services ,Axial Spondyloarthritis ,Spondylitis - Abstract
ObjectivesTo investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).MethodsDemographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression.ResultsOf 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25–2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39–2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42–0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19.ConclusionOlder age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.
- Published
- 2023
65. Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany
- Author
-
Katinka Albrecht, Sebastian Binder, Kirsten Minden, Denis Poddubnyy, Anne C. Regierer, Anja Strangfeld, and Johanna Callhoff
- Subjects
Rheumatology - Abstract
Objective This study aimed to update the prevalence estimates of inflammatory rheumatic diseases (IRD) in Germany. Methods A systematic literature search in PubMed and Web of Science (last search 08 November 2022) identified original articles (regional and nationwide surveys and claims data analyses for arthritides, connective tissue diseases, and vasculitides) on prevalences for the period 2014–2022. Data sources, collection period, case definition, and risk of bias are reported. Prevalences were estimated from available national data, with consideration of international data. Results Screening by two authors yielded 263 hits, of which 18 claims data analyses and 2 surveys met the inclusion criteria. Prevalences ranged from 0.42 to 1.85% (rheumatoid arthritis), 0.32–0.5% (ankylosing spondylitis), 0.11–0.32% (psoriatic arthritis), 0.037–0.14% (systemic lupus erythematosus), 0.07–0.77% (Sjögren’s disease/sicca syndrome), 0.14–0.15% (polymyalgia rheumatica, ≥ 40 years), 0.04–0.05% (giant cell arteritis, ≥ 50 years), and 0.015–0.026% (ANCA-associated vasculitis). The risk of bias was moderate in 13 and high in 7 studies. Based on the results, we estimate the prevalence of IRD in Germany to be 2.2–3.0%, which corresponds to approximately 1.5–2.1 million affected individuals. The prevalence of juvenile idiopathic arthritis was reported to be around 0.10% (0.07–0.10%) of 0–18-year-olds, corresponding to about 14,000 children and adolescents in Germany. Conclusion This systematic review shows an increase in the prevalence of IRD in Germany, which is almost exclusively based on claims data analyses. In the absence of multistage population studies, the available data are, overall, uncertain sources for prevalence estimates, with a moderate to high risk of bias.
- Published
- 2023
66. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
- Author
-
Zara Izadi, Milena A Gianfrancesco, Gabriela Schmajuk, Lindsay Jacobsohn, Patricia Katz, Stephanie Rush, Clairissa Ja, Tiffany Taylor, Kie Shidara, Maria I Danila, Katherine D Wysham, Anja Strangfeld, Elsa F Mateus, Kimme L Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Samar Al-Emadi, Jeffrey A Sparks, Tiffany Y-T Hsu, Naomi J Patel, Leanna Wise, Emily Gilbert, Alí Duarte-García, Maria O Valenzuela-Almada, Manuel F Ugarte-Gil, Lotta Ljung, Carlo A Scirè, Greta Carrara, Eric Hachulla, Christophe Richez, Patrice Cacoub, Thierry Thomas, Maria J Santos, Miguel Bernardes, Rebecca Hasseli, Anne Regierer, Hendrik Schulze-Koops, Ulf Müller-Ladner, Guillermo Pons-Estel, Romina Tanten, Romina E Nieto, Cecilia N Pisoni, Yohana S Tissera, Ricardo Xavier, Claudia D Lopes Marques, Gecilmara C S Pileggi, Philip C Robinson, Pedro M Machado, Emily Sirotich, Jean W Liew, Jonathan S Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Monique Gore-Massy, Zachary S Wallace, Jinoos Yazdany, Brahim Dahou, Gimena Gómez, Karen Roberts, Roberto M Baez, Vanessa V Castro Coello, María J Haye Salinas, Federico N Maldonado, Alvaro A Reyes, Gelsomina Alle, Hernán Maldonado Ficco, Romina Nieto, Carla Gobbi, Yohana Tissera, Cecilia Pisoni, Alba Paula, Juan A Albiero, Maria M Schmid, Micaela Cosatti, Maria J Gamba, Carlevaris Leandro, María A Cusa, Noelia German, Veronica Bellomio, Lorena Takashima, Mariana Pera, Karina Cogo, Maria S Gálvez Elkin, María A Medina, Veronica Savio, Romina Rojas Tessel, Rodolfo P Alamino, Marina L Werner, Sofía Ornella, Luciana Casalla, Maria de la Vega, María Severina, Mercedes García, Luciana Gonzalez Lucero, Cecilia Romeo, Sebastián Moyano, Tatiana Barbich, Ana Bertoli, Andrea Baños, Sandra Petruzzelli, Carla Matellan, Silvana Conti, Maria A Lazaro, Gustavo F Rodriguez Gil, Fabian Risueño, Maria I Quaglia, Julia Scafati, Natalia L Cuchiaro, Jonathan E Rebak, Susana I Pineda, María E Calvo, Eugenia Picco, Josefina G Yanzi, Pablo Maid, Debora Guaglianone, Julieta S Morbiducci, Sabrina Porta, Natalia Herscovich, José L Velasco Zamora, Boris Kisluk, Maria S Castaños Menescardi, Rosana Gallo, María V Martire, Carla Maldini, Cecilia Goizueta, Sabrina S de la Vega Fernandez, Carolina Aeschlimann, Gisela Subils, Eva Rath, Yves Piette, Mieke Devinck, Bea Maeyaert, Francinne Machado Ribeiro, Sandra L Euzebio Ribeiro, Marcelo Pinheiro, Sebastián Ibáñez, Anne-Marie Chassin Trubert, Lingli Dong, Lui Cajas, Marko Barešić, Branimir Anić, Melanie-Ivana Ćulo, Tea A Pavelić, Kristina K Stranski, Boris Karanovic, Jiri Vencovsky, Marta Píchová, Maria Filkova, Hesham Hamoud, Dimitrios Vassilopoulos, Gabriela M Guzman Melgar, Ho So, Márta Király, Mahdi Vojdanian, Alexandra Balbir Gurman, Fatemah Abutiban, Julija Zepa, Inita Bulina, Loreta Bukauskiene, Beatriz E Zazueta Montiel, Angel A Castillo Ortiz, Erick Zamora Tehozol, David Vega Morales, Diana Cervántes Rosete, Eduardo Martín Nares, Tatiana S Rodriguez Reyna, Marina Rull Gabayet, Deshiré Alpízar Rodríguez, Fedra Irazoque, Xochitl Jimenez, Lenny Geurts van Bon, Theo Zijlstra, Monique Hoekstra, Nasra Al Adhoubi, Babur Salim, Enrique Giraldo, Ariel Salinas, Manuel Ugarte Gil, Jarosław Nowakowski, Richard Conway, Rachael Flood, Geraldine McCarthy, Ioana Felea, Ileana Filipescu, Simona Rednic, Laura Groseanu, Maria M Tamas, Vanda Mlynarikova, Martina Skamlova, Martin Zlnay, Dagmar Mičeková, Lubica Capova, Zelmira Macejova, Emőke Šteňová, Helena Raffayova, Gabriela Belakova, Eva Strakova, Marieta Senčarová, Soňa Žlnayová, Anna Sabová, Daniela Spisakova, Mária Oetterová, Olga Lukacova, Martina Bakosova, Alojzija Hocevar, Natalia de la Torre Rubio, Juan J Alegre Sancho, Montserrat Corteguera Coro, Juan C Cobeta Garcia, Maria C Torres Martin, Jose Campos, Jose A Gomez Puerta, Gozd K Yardimci, Servet Akar, Ozan C Icacan, Selda ÇELİK, Viktoriia Vasylets, Su-Ann Yeoh, Claire Vandevelde, Sasha Dunt, Jane Leeder, Elizabeth Macphie, Rosaria Salerno, Christine Graver, Katie Williams, Sheila O'Reilly, Kirsty Devine, Jennifer Tyler, Elizabeth Warner, James Pilcher, Samir Patel, Elena Nikiphorou, Laura Chadwick, Caroline M Jones, Beverley Harrison, Lucy Thornton, Diana O'Kane, Lucia Fusi, Audrey Low, Sarah Horton, Shraddha Jatwani, Sara Baig, Hammad Bajwa, Vernon Berglund, Angela Dahle, Walter Dorman, Jody Hargrove, Maren Hilton, Nicholas Lebedoff, Susan Leonard, Jennifer Morgan, Emily Pfeifer, Archibald Skemp, Jeffrey Wilson, Anne Wolff, Eduardo Cepeda, Derrick Todd, Denise Hare, Cassandra Calabrese, Christopher Adams, Arezou Khosroshahi, Adam Kilian, Douglas White, Melanie Winter, Theodore Fields, Caroline Siegel, Nicole Daver, Melissa Harvey, Neil Kramer, Concetta Lamore, Suneya Hogarty, Karen Yeter, Faizah Siddique, Byung Ban, Tamar Tanner, Eric Ruderman, William Davis, Robert Quinet, Evangeline Scopelitis, Karen Toribio, Tameka Webb Detiege, Jerald Zakem, Khurram Abbass, Gilbert Kepecs, Lilliam Miranda, Michael Guma, Ammar Haikal, Sushama Mody, Daric Mueller, Arundathi Jayatilleke, JoAnn Zell, Alison Bays, Kathryn Dao, Fatemeh Ezzati, Deborah Parks, David Karp, Guillermo Quiceno, Izadi, Z, Gianfrancesco, M, Schmajuk, G, Jacobsohn, L, Katz, P, Rush, S, Ja, C, Taylor, T, Shidara, K, Danila, M, Wysham, K, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Al-Emadi, S, Sparks, J, Hsu, T, Patel, N, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Ugarte-Gil, M, Ljung, L, Scire, C, Carrara, G, Hachulla, E, Richez, C, Cacoub, P, Thomas, T, Santos, M, Bernardes, M, Hasseli, R, Regierer, A, Schulze-Koops, H, Muller-Ladner, U, Pons-Estel, G, Tanten, R, Nieto, R, Pisoni, C, Tissera, Y, Xavier, R, Lopes Marques, C, Pileggi, G, Robinson, P, Machado, P, Sirotich, E, Liew, J, Hausmann, J, Sufka, P, Grainger, R, Bhana, S, Gore-Massy, M, Wallace, Z, Yazdany, J, Dahou, B, Gomez, G, Roberts, K, Baez, R, Castro Coello, V, Haye Salinas, M, Maldonado, F, Reyes, A, Alle, G, Maldonado Ficco, H, Gobbi, C, Paula, A, Albiero, J, Schmid, M, Cosatti, M, Gamba, M, Leandro, C, Cusa, M, German, N, Bellomio, V, Takashima, L, Pera, M, Cogo, K, Galvez Elkin, M, Medina, M, Savio, V, Rojas Tessel, R, Alamino, R, Werner, M, Ornella, S, Casalla, L, de la Vega, M, Severina, M, Garcia, M, Gonzalez Lucero, L, Romeo, C, Moyano, S, Barbich, T, Bertoli, A, Banos, A, Petruzzelli, S, Matellan, C, Conti, S, Lazaro, M, Rodriguez Gil, G, Risueno, F, Quaglia, M, Scafati, J, Cuchiaro, N, Rebak, J, Pineda, S, Calvo, M, Picco, E, Yanzi, J, Maid, P, Guaglianone, D, Morbiducci, J, Porta, S, Herscovich, N, Velasco Zamora, J, Kisluk, B, Castanos Menescardi, M, Gallo, R, Martire, M, Maldini, C, Goizueta, C, de la Vega Fernandez, S, Aeschlimann, C, Subils, G, Rath, E, Piette, Y, Devinck, M, Maeyaert, B, Machado Ribeiro, F, Euzebio Ribeiro, S, Pinheiro, M, Ibanez, S, Chassin Trubert, A, Dong, L, Cajas, L, Baresic, M, Anic, B, Culo, M, Pavelic, T, Stranski, K, Karanovic, B, Vencovsky, J, Pichova, M, Filkova, M, Hamoud, H, Vassilopoulos, D, Guzman Melgar, G, So, H, Kiraly, M, Vojdanian, M, Balbir Gurman, A, Abutiban, F, Zepa, J, Bulina, I, Bukauskiene, L, Zazueta Montiel, B, Castillo Ortiz, A, Zamora Tehozol, E, Vega Morales, D, Cervantes Rosete, D, Martin Nares, E, Rodriguez Reyna, T, Rull Gabayet, M, Alpizar Rodriguez, D, Irazoque, F, Jimenez, X, Geurts van Bon, L, Zijlstra, T, Hoekstra, M, Al Adhoubi, N, Salim, B, Giraldo, E, Salinas, A, Ugarte Gil, M, Nowakowski, J, Conway, R, Flood, R, Mccarthy, G, Felea, I, Filipescu, I, Rednic, S, Groseanu, L, Tamas, M, Mlynarikova, V, Skamlova, M, Zlnay, M, Micekova, D, Capova, L, Macejova, Z, Stenova, E, Raffayova, H, Belakova, G, Strakova, E, Sencarova, M, Zlnayova, S, Sabova, A, Spisakova, D, Oetterova, M, Lukacova, O, Bakosova, M, Hocevar, A, de la Torre Rubio, N, Alegre Sancho, J, Corteguera Coro, M, Cobeta Garcia, J, Torres Martin, M, Campos, J, Gomez Puerta, J, Yardimci, G, Akar, S, Icacan, O, Celik, S, Vasylets, V, Yeoh, S, Vandevelde, C, Dunt, S, Leeder, J, Macphie, E, Salerno, R, Graver, C, Williams, K, O'Reilly, S, Devine, K, Tyler, J, Warner, E, Pilcher, J, Patel, S, Nikiphorou, E, Chadwick, L, Jones, C, Harrison, B, Thornton, L, O'Kane, D, Fusi, L, Low, A, Horton, S, Jatwani, S, Baig, S, Bajwa, H, Berglund, V, Dahle, A, Dorman, W, Hargrove, J, Hilton, M, Lebedoff, N, Leonard, S, Morgan, J, Pfeifer, E, Skemp, A, Wilson, J, Wolff, A, Cepeda, E, Todd, D, Hare, D, Calabrese, C, Adams, C, Khosroshahi, A, Kilian, A, White, D, Winter, M, Fields, T, Siegel, C, Daver, N, Harvey, M, Kramer, N, Lamore, C, Hogarty, S, Yeter, K, Siddique, F, Ban, B, Tanner, T, Ruderman, E, Davis, W, Quinet, R, Scopelitis, E, Toribio, K, Webb Detiege, T, Zakem, J, Abbass, K, Kepecs, G, Miranda, L, Guma, M, Haikal, A, Mody, S, Mueller, D, Jayatilleke, A, Zell, J, Bays, A, Dao, K, Ezzati, F, Parks, D, Karp, D, Quiceno, G, and Repositório da Universidade de Lisboa
- Subjects
health care disparity ,Immunology ,air pollution ,cohort analysi ,mortality rate ,Autoimmune Disease ,Article ,coronavirus disease 2019 ,biocontainment ,Rheumatology ,male ,cardiovascular disease ,environmental factor ,death ,geographic distribution ,Immunology and Allergy ,follow up ,controlled study ,human ,population density ,outcome assessment ,rheumatic disease ,diabetes mellitu ,adult ,Prevention ,market ,temperature ,mortality ,United Kingdom ,Europe ,aged ,female ,workplace ,Good Health and Well Being ,human development ,particulate matter 2.5 ,statistical analysi ,North America ,incidence ,life expectancy ,social aspect ,COVID-19 Global Rheumatology Alliance Registry ,observational study ,demographic - Abstract
Published by Elsevier Ltd., Background: Differences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally. Methods: In this observational study, we derived individual-level data on adults (aged 18-99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death. Findings: 14 044 patients from 23 countries were included in the analyses. 10 178 (72·5%) individuals were female and 3866 (27·5%) were male, with a mean age of 54·4 years (SD 15·6). Air pollution (odds ratio 1·10 per 10 μg/m3 [95% CI 1·01-1·17]; p=0·0105), proportion of the population aged 65 years or older (1·19 per 1% increase [1·10-1·30]; p, MAG is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K01 AR070585 and K24 AR074534 [JY]). KDW is supported by the Department of Veterans Affairs and the Rheumatology Research Foundation Scientist Development award. JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253, and P30 AR072577), the Rheumatology Research Foundation (K Supplement Award and R Bridge Award), the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund. NJP is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258). AD-G is supported by grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation. RH was supported by the Justus-Liebig University Giessen Clinician Scientist Program in Biomedical Research to work on this registry. JY is supported by grants from the National Institutes of Health (K24 AR074534 and P30 AR070155).
- Published
- 2022
67. 33 Jahre DRFZ: Epidemiologie und Versorgungsforschung
- Author
-
Anja Strangfeld, Katinka Albrecht, Anne Regierer, Johanna Callhoff, Angela Zink, and Kirsten Minden
- Subjects
Rheumatology - Published
- 2022
68. Vorwort
- Author
-
Possinger, Kurt, primary, Regierer, Anne C., additional, and Eucker, Jan, additional
- Published
- 2018
- Full Text
- View/download PDF
69. Tumor- und therapieassoziierte Notfälle
- Author
-
Regierer, Anne C., primary and Schulz, Carsten-Oliver, additional
- Published
- 2018
- Full Text
- View/download PDF
70. Gynäkologische Tumoren
- Author
-
Regierer, Anne C., primary, Eucker, Jan, additional, and Possinger, Kurt, additional
- Published
- 2018
- Full Text
- View/download PDF
71. Adressen
- Author
-
Possinger, Kurt, primary, Regierer, Anne Constanze, additional, Eucker, Jan, additional, Dieing, Annette, additional, Flath, Bernd, additional, Folprecht, Gunnar, additional, Geißler, Michael, additional, Hiller, Erhard, additional, Hochhaus, Andreas, additional, Jehn, Christian, additional, Keilholz, Ulrich, additional, Klinghammer, Konrad, additional, Knauf, Wolfgang, additional, Kolb, Hans-Jochem, additional, Lüftner, Diana, additional, Maasberg, Sebastian, additional, Möhlig, Matthias, additional, Oettle, Helmut, additional, Pape, Ulrich-Frank, additional, Platzbecker, Uwe, additional, Possinger, Kurt, additional, Rank, Andreas, additional, Reichardt, Peter, additional, Rick, Oliver, additional, Riess, Hanno, additional, Ruhnke, Markus, additional, Schaich, Markus, additional, Schalhorn, Andreas, additional, Schmaelter, Ann-Kristin, additional, Schmittel, Alexander, additional, Scholz, Christian, additional, Schrezenmeier, Hubert, additional, Schulz, Carsten-Oliver, additional, Sockel, Katja, additional, and Wiedenmann, Bertram, additional
- Published
- 2018
- Full Text
- View/download PDF
72. Supportive Therapien
- Author
-
C. Regierer, Anne, primary, Schulz, Carsten-Oliver, additional, and Possinger, Kurt, additional
- Published
- 2018
- Full Text
- View/download PDF
73. Spezielles in der Onkologie und Hämatologie
- Author
-
Schulz, Carsten-Oliver, primary, Flath, Bernd, additional, Regierer, Anne C., additional, and Possinger, Kurt, additional
- Published
- 2018
- Full Text
- View/download PDF
74. Mammakarzinome
- Author
-
Eucker, Jan, primary, Regierer, Anne C., additional, and Possinger, Kurt, additional
- Published
- 2018
- Full Text
- View/download PDF
75. No Increased Lethality in Covid-19 in Patients with Inflammatory Rheumatic Diseases Compared to the General Population - a Comparison of Two German Registries -
- Author
-
Hasseli, Rebecca, primary, Hanses, Frank, additional, Stecher, Melanie, additional, Specker, Christof, additional, Weise, Tobias, additional, Borgmann, Stefan, additional, Haselberger, Martina, additional, Hertenstein, Bernd, additional, Hower, Martin, additional, Hoyer, Bimba Franziska, additional, Koll, Carolin, additional, Krause, Andreas, additional, von Lilienfeld-Toal, Marie, additional, Lorenz, Hanns-Martin, additional, Merle, Uta, additional, Nunes de Miranda, Susana M., additional, Pletz, Mathias W., additional, Regierer, Anne, additional, Richter, Jutta G., additional, Rieg, Siegbert R., additional, Römmele, Christoph, additional, Rüthrich, Maria M., additional, Schulze-Koops, Hendrik, additional, Strangfeld, Anja, additional, Vehreschild, Maria, additional, Voit, Florian, additional, Voll, Reinhard, additional, Vehreschild, Jörg Janne, additional, Leipsic, Jonathon, additional, and Pfeil, Alexander, additional
- Published
- 2023
- Full Text
- View/download PDF
76. Systematisches Review zur Schätzung der Prävalenz entzündlich rheumatischer Erkrankungen in Deutschland
- Author
-
Katinka Albrecht, Sebastian Binder, Kirsten Minden, Denis Poddubnyy, Anne C. Regierer, Anja Strangfeld, and Johanna Callhoff
- Subjects
Rheumatology - Abstract
Zusammenfassung Zielsetzung Es erfolgt eine aktualisierte Schätzung der Prävalenz entzündlich rheumatischer Erkrankungen (ERE) in Deutschland. Methodik Mit einer systematischen Literaturrecherche in PubMed und Web of Science (letzte Suche am 08.11.2022) wurden Originalartikel (regionale und bundesweite Surveys und Routinedatenanalysen für Arthritiden, Kollagenosen und Vaskulitiden) zur Prävalenz von ERE für den Zeitraum 2014 bis 2022 identifiziert. Datenquellen, Erhebungszeitraum, Diagnosedefinition und das Risiko einer Verzerrung werden berichtet. Die Prävalenzen wurden anhand der verfügbaren Daten unter Berücksichtigung internationaler Angaben geschätzt. Ergebnisse Die Suche durch 2 Autorinnen ergab 263 Treffer, von denen 18 Routinedatenanalysen und 2 Surveys die Einschlusskriterien erfüllten. Die Prävalenzangaben lagen bei 0,42–1,85 % (rheumatoide Arthritis), 0,32–0,5 % (ankylosierende Spondylitis), 0,11–0,32 % (Psoriasisarthritis), 0,037–0,14 % (systemischer Lupus erythematodes), 0,07–0,77 % (Sjögren/Sicca-Syndrom), 0,14–0,15 % (Polymyalgia rheumatica, ab 40 Jahre), 0,04–0,05 % (Riesenzellarteriitis, ab 50 Jahre) und 0,015–0,026 % (ANCA-assoziierte Vaskulitis). Das Bias-Risiko war in 13 Studien moderat, in 7 Studien hoch. Anhand dieser Ergebnisse schätzen wir die Prävalenz von ERE in Deutschland auf 2,2–3,0 %. Dies entspricht in etwa 1,5 bis 2,1 Mio. Betroffenen. Die Prävalenz der juvenilen idiopathischen Arthritis wurde mit ca. 0,10 % (0,07–0,13 %) der 0‑ bis 18-Jährigen angegeben, was etwa 14.000 Kindern und Jugendlichen in Deutschland entspricht. Schlussfolgerung Dieses systematische Review zeigt einen Anstieg der Prävalenzen von ERE in Deutschland, basiert jedoch fast ausschließlich auf Routinedatenanalysen. In Ermangelung mehrstufiger Bevölkerungsstudien sind die vorliegenden Daten bei moderat bis hohem Verzerrungsrisiko insgesamt unsichere Quellen für Prävalenzschätzungen.
- Published
- 2023
77. [Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. German version]
- Author
-
Katinka, Albrecht, Sebastian, Binder, Kirsten, Minden, Denis, Poddubnyy, Anne C, Regierer, Anja, Strangfeld, and Johanna, Callhoff
- Abstract
To update the estimated prevalence of inflammatory rheumatic diseases (IRD) in Germany.A systematic literature search in PubMed and Web of Science (last search 8 November 2022) identified original articles (regional and nationwide surveys and routine data analyses for arthritides, connective tissue diseases, and vasculitides) on the prevalence for the period 2014-2022. Data sources, collection period, case definition, and risk of bias are reported. The prevalences were estimated from available national data, with consideration of international data.Screening by 2 authors yielded 263 hits, of which 18 routine data analyses and 2 surveys met the inclusion criteria. Prevalence data ranged from 0.42% to 1.85% (rheumatoid arthritis), 0.32-0.5% (ankylosing spondylitis), 0.11-0.32% (psoriatic arthritis), 0.037-0.14% (systemic lupus erythematosus), 0.07-0.77% (Sjoegren's disease/sicca syndrome), 0.14-0.15% (polymyalgia rheumatica, ≥ 40 years), 0.04-0.05% (giant cell arteritis, ≥ 50 years), and 0.015-0.026% (ANCA-associated vasculitis). The risk of bias was moderate in 13 and high in 7 studies. Based on the results, we estimate the prevalence of IRD in Germany to be 2.2-3.0%, which corresponds to approximately 1.5-2.1 million affected individuals. Prevalence data of juvenile idiopathic arthritis was reported to be around 0.10% (0.07-0.10%) of patients 0-18 years old, corresponding to about 14,000 children and adolescents in Germany.This systematic review shows an increase in the prevalence of IRD in Germany, which is almost exclusively based on routine data analyses. In the absence of multistage population studies, the available data are overall uncertain sources for prevalence estimates at moderate to high risk of bias.ZIELSETZUNG: Es erfolgt eine aktualisierte Schätzung der Prävalenz entzündlich rheumatischer Erkrankungen (ERE) in Deutschland.Mit einer systematischen Literaturrecherche in PubMed und Web of Science (letzte Suche am 08.11.2022) wurden Originalartikel (regionale und bundesweite Surveys und Routinedatenanalysen für Arthritiden, Kollagenosen und Vaskulitiden) zur Prävalenz von ERE für den Zeitraum 2014 bis 2022 identifiziert. Datenquellen, Erhebungszeitraum, Diagnosedefinition und das Risiko einer Verzerrung werden berichtet. Die Prävalenzen wurden anhand der verfügbaren Daten unter Berücksichtigung internationaler Angaben geschätzt.Die Suche durch 2 Autorinnen ergab 263 Treffer, von denen 18 Routinedatenanalysen und 2 Surveys die Einschlusskriterien erfüllten. Die Prävalenzangaben lagen bei 0,42–1,85 % (rheumatoide Arthritis), 0,32–0,5 % (ankylosierende Spondylitis), 0,11–0,32 % (Psoriasisarthritis), 0,037–0,14 % (systemischer Lupus erythematodes), 0,07–0,77 % (Sjögren/Sicca-Syndrom), 0,14–0,15 % (Polymyalgia rheumatica, ab 40 Jahre), 0,04–0,05 % (Riesenzellarteriitis, ab 50 Jahre) und 0,015–0,026 % (ANCA-assoziierte Vaskulitis). Das Bias-Risiko war in 13 Studien moderat, in 7 Studien hoch. Anhand dieser Ergebnisse schätzen wir die Prävalenz von ERE in Deutschland auf 2,2–3,0 %. Dies entspricht in etwa 1,5 bis 2,1 Mio. Betroffenen. Die Prävalenz der juvenilen idiopathischen Arthritis wurde mit ca. 0,10 % (0,07–0,13 %) der 0‑ bis 18-Jährigen angegeben, was etwa 14.000 Kindern und Jugendlichen in Deutschland entspricht.Dieses systematische Review zeigt einen Anstieg der Prävalenzen von ERE in Deutschland, basiert jedoch fast ausschließlich auf Routinedatenanalysen. In Ermangelung mehrstufiger Bevölkerungsstudien sind die vorliegenden Daten bei moderat bis hohem Verzerrungsrisiko insgesamt unsichere Quellen für Prävalenzschätzungen.
- Published
- 2022
78. Future of Medicine: Models in Predictive Diagnostics and Personalized Medicine
- Author
-
for the ITFoM Consortium, Regierer, Babette, Zazzu, Valeria, Sudbrak, Ralf, Kühn, Alexander, Lehrach, Hans, Seitz, Harald, editor, and Schumacher, Sarah, editor
- Published
- 2013
- Full Text
- View/download PDF
79. Ten simple rules on how to develop a stakeholder engagement plan
- Author
-
Hollmann, Susanne, Regierer, Babette, Bechis, Jaele, Tobin, Lesley, and D’Elia, Domenica
- Subjects
Cellular and Molecular Neuroscience ,Computational Theory and Mathematics ,Ecology ,Stakeholder Participation ,Modeling and Simulation ,Communication ,Genetics ,Humans ,Molecular Biology ,Ecology, Evolution, Behavior and Systematics ,Research Personnel - Abstract
To make research responsible and research outcomes meaningful, it is necessary to communicate our research and to involve as many relevant stakeholders as possible, especially in application-oriented—including information and communications technology (ICT)—research. Nowadays, stakeholder engagement is of fundamental importance to project success and achieving the expected impact and is often mandatory in a third-party funding context. Ultimately, research and development can only be successful if people react positively to the results and benefits generated by a project. For the wider acceptance of research outcomes, it is therefore essential that the public is made aware of and has an opportunity to discuss the results of research undertaken through two-way communication (interpersonal communication) with researchers. Responsible Research and Innovation (RRI), an approach that anticipates and assesses potential implications and societal expectations regarding research and innovation, aims to foster inclusive and sustainable research and innovation. Research and innovation processes need to become more responsive and adaptive to these grand challenges. This implies, among other things, the introduction of broader foresight and impact assessments for new technologies beyond their anticipated market benefits and risks. Therefore, this article provides a structured workflow that explains “how to develop a stakeholder engagement plan” step by step.
- Published
- 2022
80. Merkmale von Patient*innen mit Psoriasis-Arthritis in dermatologischer und rheumatologischer Versorgung: Eine Analyse zweier Krankheitsregister
- Author
-
Kühl, L, Lindner, L, Augustin, M, Weiss, A, Rustenbach, SJ, Mrowietz, U, Behrens, F, Strangfeld, A, and Regierer, A
- Subjects
ddc: 610 ,Medicine and health - Abstract
Hintergrund und Stand (inter)nationaler Forschung: Die Psoriasis-Arthritis (PsA) ist eine chronisch entzündliche Erkrankung, die den Bewegungsapparat, die Haut und die Nägel betrifft. Die Diagnose und Versorgung der PsA-Patient*innen erfolgt in Deutschland in der Regel durch Dermatolog*innen [zum vollständigen Text gelangen Sie über die oben angegebene URL]
- Published
- 2022
- Full Text
- View/download PDF
81. Durchbruchinfektionen bei vollständig geimpften Patienten mit entzündlich-rheumatischen Erkrankungen – Daten aus dem COVID19-Rheuma.de-Register
- Author
-
Hasseli, Rebecca, Hoyer, Bimba F., Huppke, Liam, Lorenz, Hanns-Martin, Pfeil, Alexander, Regierer, Anne, Richter, Jutta, Schmeiser, Tim, Strangfeld, Anja, Voll, Reinhard, Krause, Andreas, Schulze-Koops, Hendrik, Specker, Christof, and Müller-Ladner, Ulf
- Subjects
Medicine and health - Abstract
Einleitung: COVID-19-Impfungen reduzieren nachweislich das Risiko für schwere Verläufe einer SARS-CoV-2-Infektion. Auch bei Patienten mit entzündlich-rheumatischen Erkrankungen (ERE) und bei Patienten unter Immunmodulation konnte mehrheitlich eine ausreichende humorale Immunantwort auf [zum vollständigen Text gelangen Sie über die oben angegebene URL]
- Published
- 2022
- Full Text
- View/download PDF
82. Vergleich von Patienten mit axialer Psoriasis-Arthritis mit axSpA-Patienten mit begleitender Psoriasis
- Author
-
Regierer, Anne, Weiß, Anja, Baraliakos, Xenofon, Behrens, Frank, Poddubnyy, Denis, Schett, Georg, Lorenz, Hanns-Martin, Worsch, Matthias, and Strangfeld, Anja
- Subjects
Medicine and health - Abstract
Einleitung: Psoriasis-Arthritis (PsA) ist eine chronisch-entzündliche Erkrankung, bei der das muskuloskeletale System (periphere Arthritis, Achsenskelettbeteiligung, Enthesitis) sowie Haut und Hautanhang betroffen sind. Diagnostische Kriterien für die axiale Beteiligung sind bisher nicht ausreichend [zum vollständigen Text gelangen Sie über die oben angegebene URL]
- Published
- 2022
- Full Text
- View/download PDF
83. Verträglichkeit und Sicherheit von COVID-19-Impfstoffen nach Erstimpfung bei Patienten mit rheumatischen Erkrankungen
- Author
-
Hasseli, Rebecca, Hoyer, Bimba F., Lorenz, Hanns-Martin, Pfeil, Alexander, Regierer, Anne, Richter, Jutta G., Schmeiser, Tim, Strangfeld, Anja, Voll, Reinhard, Krause, Andreas, Specker, Christof, Müller-Ladner, Ulf, and Schulze-Koops, Hendrik
- Subjects
Medicine and health - Abstract
Einleitung: Zu Beginn der Impfkampagne herrschte Ungewissheit bezüglich der Verträglichkeit und Sicherheit der neuartigen Impfstoffe gegen SARS-CoV-2 bei Patienten mit rheumatischen Erkrankungen (RE) mit und ohne Immunmodulation. Es lagen insbesondere keine Daten bezüglich der Verträglichkeit [zum vollständigen Text gelangen Sie über die oben angegebene URL]
- Published
- 2022
- Full Text
- View/download PDF
84. Charakterisierung von Patient*innen mit Psoriasis-Arthritis in dermatologischer und rheumatologischer Versorgung: Eine Analyse zweier Krankheitsregister
- Author
-
Lindner, Lisa, Augustin, Matthias, Kühl, Laura, Weiß, Anja, Rustenbach, Stephan, Baraliakos, Xenofon, Feuchtenberger, Martin, Mrowietz, Ulrich, Thaci, Diamant, Staubach, Petra, Behrens, Frank, Strangfeld, Anja, and Regierer, Anne
- Subjects
Medicine and health - Abstract
Einleitung: Die Psoriasis-Arthritis (PsA) ist eine chronisch entzündliche Erkrankung, die den Bewegungsapparat, die Haut und die Nägel betrifft. Die therapeutische Betreuung erfolgt in der Regel durch Dermatolog*innen oder Rheumatolog*innen. Ziel der Untersuchung ist es, Patient*innen [zum vollständigen Text gelangen Sie über die oben angegebene URL]
- Published
- 2022
- Full Text
- View/download PDF
85. Zeitliche Trends im Verlauf von SARS-CoV-2-Infektionen seit Beginn des COVID19-Rheuma.de-Registers
- Author
-
Hasseli, Rebecca, Hoyer, Bimba F., Lorenz, Hanns-Martin, Pfeil, Alexander, Regierer, Anne, Richter, Jutta, Schmeiser, Tim, Strangfeld, Anja, Voll, Reinhard, Krause, Andreas, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, and Specker, Christof
- Subjects
Medicine and health - Abstract
Einleitung: Seit Beginn der Pandemie haben Virusmutationen, Zulassung von Impfstoffen, Medikamente zur Therapie von COVID-19 sowie der fortschreitende Informationsgewinn zum Umgang mit dem Coronavirus Einfluss auf den Verlauf der Pandemie genommen. Zur Frage, inwieweit sich die klinischen Verläufe [zum vollständigen Text gelangen Sie über die oben angegebene URL]
- Published
- 2022
- Full Text
- View/download PDF
86. The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study
- Author
-
Regierer, Anne C., primary, Weiß, Anja, additional, Kiltz, Uta, additional, Sieper, Joachim, additional, Schwarze, Ilka, additional, Bohl-Bühler, Martin, additional, Kellner, Herbert, additional, Poddubnyy, Denis, additional, Zink, Angela, additional, Braun, Jürgen, additional, Listing, Joachim, additional, and Strangfeld, Anja, additional
- Published
- 2022
- Full Text
- View/download PDF
87. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients
- Author
-
Regierer, A.C., Wolters, R., Ufen, M.-P., Weigel, A., Novopashenny, I., Köhne, C.H., Samonigg, H., Eucker, J., Possinger, K., and Wischnewsky, M.B.
- Published
- 2014
- Full Text
- View/download PDF
88. Metastatic breast cancer: are we treating the same patients as in the past?
- Author
-
Ufen, M.-P., Köhne, C.H., Wischneswky, M., Wolters, R., Novopashenny, I., Fischer, J., Constantinidou, M., Possinger, K., and Regierer, A.C.
- Published
- 2014
- Full Text
- View/download PDF
89. Deutsches Register www.Covid19-Rheuma.de
- Author
-
Anja Strangfeld, Reinhard E. Voll, Alexander Pfeil, Christof Specker, Rebecca Hasseli, Hanns-Martin Lorenz, Hendrik Schulze-Koops, Bimba F. Hoyer, T. Schmeiser, Ulf Müller-Ladner, Anne C. Regierer, Andreas Krause, and Jutta G Richter
- Subjects
030203 arthritis & rheumatology ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Medical laboratory ,Context (language use) ,Rheumatology ,Patient care ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Cohort ,Pandemic ,medicine ,In patient ,030212 general & internal medicine ,Intensive care medicine ,business - Abstract
ZusammenfassungDurch das COVID-19-Register (www.covid19-rheuma.de) der Deutschen Gesellschaft für Rheumatologie erfolgte erstmalig die Erfassung und systematische Evaluation einer viralen Infektion bei Patienten mit entzündlich rheumatischen Erkrankungen (ERE). Hierdurch war und ist eine schnelle Generierung von wissenschaftlichen Daten möglich, welche helfen, die Betreuung von Patienten mit ERE im Rahmen der Pandemie zu verbessern. Neben der Bestätigung allgemeiner Risikofaktoren – auch für Patienten mit ERE – wie Patientenalter und Komorbiditäten (z. B. kardiovaskuläre, chronische Lungen- und Nierenerkrankungen) konnten die Einnahme von Glukokortikoiden und die Krankheitsaktivität der rheumatischen Erkrankung als krankheitsspezifische Risikofaktoren für die Notwendigkeit einer stationären Behandlung wegen COVID-19 identifiziert werden. Auswertungen der kontinuierlich wachsenden Kohorte von Patienten mit entzündlich rheumatischen Erkrankungen und einer COVID-19-Infektion erlauben, Handlungsempfehlungen für die Betreuung der Patienten auf eine bessere Evidenz zu stützen. Die Kooperation mit internationalen rheumatologischen Registern (z. B. europäisches COVID-19-Register für ERE) ermöglicht Analysen aggregierter Kohortendaten von Patienten mit entzündlich rheumatischen Erkrankungen und einer SARS-CoV-2-Infektion für internationale Vergleiche und statistisch noch besser abgesicherte Aussagen.
- Published
- 2021
90. Mammakarzinome
- Author
-
Eucker, Jan, primary, Regierer, Anne C., additional, and Possinger, Kurt, additional
- Published
- 2017
- Full Text
- View/download PDF
91. Supportive Therapie
- Author
-
Regierer, Anne C., primary, Schulz, Carsten-Oliver, additional, Flath, Bernd, additional, and Possinger, Kurt, additional
- Published
- 2017
- Full Text
- View/download PDF
92. Vorwort
- Author
-
Possinger, Kurt, primary, Regierer, Anne, additional, and Eucker, Jan, additional
- Published
- 2017
- Full Text
- View/download PDF
93. Tumor- und therapieassoziierte Notfälle
- Author
-
Regierer, Anne C., primary and Schulz, Carsten-Oliver, additional
- Published
- 2017
- Full Text
- View/download PDF
94. Gynäkologische Tumoren
- Author
-
Regierer, Anne C., primary, Eucker, Jan, additional, and Possinger, Kurt, additional
- Published
- 2017
- Full Text
- View/download PDF
95. Anhang
- Author
-
Regierer, Anne C., primary and Possinger, Kurt, additional
- Published
- 2017
- Full Text
- View/download PDF
96. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
- Author
-
Mercer, Louise K, Regierer, Anne C, Mariette, Xavier, Dixon, William G, Baecklund, Eva, Hellgren, Karin, Dreyer, Lene, Hetland, Merete Lund, Cordtz, René, Hyrich, Kimme, Strangfeld, Anja, Zink, Angela, Canhao, Helena, Hernandez, M Victoria, Tubach, Florence, Gottenberg, Jacques-Eric, Morel, Jacques, Zavada, Jakub, Iannone, Florenzo, Askling, Johan, and Listing, Joachim
- Published
- 2017
- Full Text
- View/download PDF
97. Solide Tumoren
- Author
-
Possinger, Kurt, Regierer, Anne C., Börgermann, Christof, vom Dorp, Frank, Otto, Thomas, Rübben, Herbert, Krege, Susanne, Hanf, Volker, Kreienberg, Rolf, Eberhardt, Wilfried, Issels, Rolf D., Riess, Hanno, Bokemeyer, Carsten, Wierecky, Jan, and Schölmerich, Jürgen, editor
- Published
- 2007
- Full Text
- View/download PDF
98. Solide Tumoren
- Author
-
Possinger, Kurt, Regierer, Anne C., Otto, Thomas, Rübben, Herbert, Krege, Susanne, Hanf, Volker, Kreienberg, Rolf, Eberhardt, Wilfried, Issels, Rolf D., Riess, Hanno, Bokemeyer, Carsten, Schölmerich, Jürgen, editor, Burdach, S., editor, Drexler, H., editor, Hallek, M., editor, Hiddemann, W., editor, Hörl, W.H., editor, Klein, H., editor, Landthaler, M., editor, Lenz, K., editor, Mann, K., editor, Mössner, J., editor, Müller-Ladner, U., editor, Reichen, J., editor, Schmiegel, W., editor, Schröder, J.O., editor, Seeger, W., editor, Stremmel, W., editor, Suttorp, N., editor, Weilemann, L.S., editor, and Wöhrle, J.C., editor
- Published
- 2005
- Full Text
- View/download PDF
99. Risikostratifizierung für Therapieentscheidungen bei Rheumatoider Arthritis
- Author
-
Katinka Albrecht, Anja Strangfeld, and Anne C. Regierer
- Subjects
030203 arthritis & rheumatology ,Gynecology ,Disease activity ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,Rheumatology ,business.industry ,medicine ,030212 general & internal medicine ,business - Abstract
ZusammenfassungUm für die Behandlung der rheumatoiden Arthritis unter der Vielzahl an zugelassenen krankheitsmodifizierenden Antirheumatika die geeignete Therapie auszuwählen, werden Patienten anhand ihres Risikos für einen ungünstigen Krankheitsverlauf stratifiziert. Die Auswahl geeigneter Parameter zur Risikostratifizierung werden in dieser Übersichtsarbeit dargestellt. Beim heutigen Therapieziel einer Remission sind hohe Krankheitsaktivität, Funktionseinschränkungen, Begleiterkrankungen und Übergewicht relevante Faktoren für einen ungünstigen Verlauf. Weitere Einflussfaktoren auf die Therapieentscheidung wie Begleiterkrankungen, Infektionsrisiko und spezielle Risikokonstellationen wie vorausgegangene schwerwiegende Infektionen oder Malignome werden in diesem Artikel diskutiert.
- Published
- 2021
100. OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES
- Author
-
Machado, P. M., primary, Schaefer, M., additional, Mahil, S., additional, Dand, N., additional, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Yiu, Z., additional, Yates, M., additional, Hyrich, K., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Wiek, D., additional, Bhana, S., additional, Gore-Massy, M., additional, Grainger, R., additional, Hausmann, J., additional, Sufka, P., additional, Sirotich, E., additional, Wallace, Z., additional, Olofsson, T., additional, Lomater, C., additional, Romeo, N., additional, Wendling, D., additional, Pham, T., additional, Miceli Richard, C., additional, Fautrel, B., additional, Silva, L., additional, Santos, H., additional, Martins, F. R., additional, Hasseli, R., additional, Pfeil, A., additional, Regierer, A., additional, Isnardi, C., additional, Soriano, E., additional, Quintana, R., additional, Omura, F., additional, Machado Ribeiro, F., additional, Pinheiro, M., additional, Bautista-Molano, W., additional, Alpizar-Rodriguez, D., additional, Saad, C., additional, Dubreuil, M., additional, Haroon, N., additional, Gensler, L. S., additional, Dau, J., additional, Jacobsohn, L., additional, Liew, J., additional, Strangfeld, A., additional, Barker, J., additional, Griffiths, C. E. M., additional, Robinson, P., additional, Yazdany, J., additional, and Smith, C., additional
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.